MOTS-c Research Guide

Also known as: Mitochondrial ORF of the 12S rRNA type-c

MOTS-c is a mitochondrial-derived peptide investigated for its roles in metabolism, insulin sensitivity, and exercise/aging biology. The research is largely preclinical with early, emerging human interest.

Evidence status: Primarily preclinical

Predominantly laboratory and animal research; human evidence is limited or absent.

Educational & research information only. This page summarizes published research and does not provide medical advice, diagnosis, treatment, or dosing guidance. These compounds are not approved treatments. Consult a qualified healthcare professional before any human use.

What it is

MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) is a short peptide encoded within mitochondrial DNA. It is studied as a signaling molecule that may communicate between mitochondria and the rest of the cell, particularly in metabolic regulation.

What researchers are studying

  • Activation of the AMPK metabolic-signaling pathway in preclinical models.
  • Investigated regulation of glucose metabolism and insulin sensitivity.
  • Proposed retrograde signaling between mitochondria and the nucleus, studied in the context of exercise and aging.

Areas studied

  • Metabolic regulation and insulin sensitivity (preclinical)
  • Exercise physiology and endurance (preclinical, early human interest)
  • Aging and metabolic stress responses (preclinical)

Evidence summary

Human research

Human evidence for MOTS-c is at an early stage. Some studies have measured endogenous MOTS-c levels in people (for example in relation to exercise or metabolic status), but controlled clinical trials of MOTS-c administration in humans are very limited. Efficacy in people is not established.

Preclinical & animal research

Most MOTS-c research is preclinical, exploring AMPK activation, glucose handling, insulin sensitivity, and resistance to metabolic stress in cell and animal models. These findings are exploratory and await confirmation in human trials.

Limitations & uncertainties

  • Human interventional data is very limited; most evidence is preclinical.
  • Much human work is observational (measuring natural levels) rather than testing administration.
  • Long-term effects and safety in humans are not established.

Safety & research considerations

MOTS-c is an investigational research peptide, not an approved treatment, and lacks controlled long-term human safety data. This page does not provide dosing guidance.

Frequently asked questions

What is a mitochondrial-derived peptide?
It is a small peptide encoded within mitochondrial DNA rather than the cell nucleus. MOTS-c is one example studied as a metabolic signaling molecule.
Is MOTS-c proven to work in humans?
No. Human interventional evidence is very limited and mostly early or observational. Its effects in people are not established.

References & further reading

Curated literature searches on PubMed and clinical-trial registries. A formal, per-study citation list is being expanded during ongoing editorial review.

Reviewed by the Pep God Research Team · Last reviewed July 10, 2026

© 2026 Pep God · All peptide guides · Privacy · Terms

Educational & research information only. Pep God is an AI-powered peptide research and education platform. We are not a doctor and do not provide medical advice, diagnosis, or treatment. Nothing on this platform should be interpreted as medical guidance. Always consult a qualified healthcare professional before using any research compounds. Users assume all risk. Terms